Yu Huang1, Zhiying Chen2, Joon Hee Jang3, Mirza S Baig4, Grant Bertolet5, Casey Schroeder6, Shengjian Huang7, Qian Hu8, Yong Zhao9, Dorothy E Lewis10, Lidong Qin11, Michael Xi Zhu12, Dongfang Liu13. 1. Department of Integrative Biology and Pharmacology, McGovern Medical School, Graduate Program in Cell and Regulatory Biology, the University of Texas Health Science Center at Houston, Houston, Tex; Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex. 2. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex; Xiangya Hospital, Xiangya School of Medicine, Central South University, Changsha, China. 3. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex; Department of Nanomedicine, Houston Methodist Research Institute, Houston, Tex. 4. Center for Biosciences and Biomedical Engineering (BSBE), Indian Institute of Technology (IIT), Indore, India. 5. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex; Department of Pathology and Immunology, Baylor College of Medicine, Houston, Tex. 6. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex. 7. Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, Houston, Tex. 8. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex; Key Laboratory of Gene Engineering of the Ministry of Education, Cooperative Innovation Center for High Performance Computing, School of Life Sciences, Sun Yat-sen University, Guangzhou, China. 9. Key Laboratory of Gene Engineering of the Ministry of Education, Cooperative Innovation Center for High Performance Computing, School of Life Sciences, Sun Yat-sen University, Guangzhou, China. 10. Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, Tex. 11. Department of Nanomedicine, Houston Methodist Research Institute, Houston, Tex. 12. Department of Integrative Biology and Pharmacology, McGovern Medical School, Graduate Program in Cell and Regulatory Biology, the University of Texas Health Science Center at Houston, Houston, Tex. Electronic address: Michael.X.Zhu@uth.tmc.edu. 13. Center for Inflammation and Epigenetics, Houston Methodist Research Institute, Houston, Tex; Department of Microbiology and Immunology, Weill Cornell Medical College, Cornell University, New York, NY. Electronic address: dliu2@houstonmethodist.org.
Abstract
BACKGROUND: The inhibitory receptor programmed cell death protein 1 (PD-1) is upregulated on a variety of immune cells, including natural killer (NK) cells, during chronic viral infection and tumorigenesis. Blockade of PD-1 or its ligands produces durable clinical responses with tolerable side effects in patients with a broad spectrum of cancers. However, the underlying molecular mechanisms of how PD-1 regulates NK cell function remain poorly characterized. OBJECTIVE: We sought to determine the effect of PD-1 signaling on NK cells. METHODS: PD-1 was overexpressed in CD16-KHYG-1 (a human NK cell line with both antibody-dependent cellular cytotoxicity through CD16 and natural cytotoxicity through NKG2D) cells and stimulated by exposing the cells to NK-sensitive target cells expressing programmed death ligand 1 (PD-L1). RESULTS: PD-1 engagement by PD-L1 specifically blocked NK cell-mediated cytotoxicity without interfering with the conjugation between NK cells and target cells. Further examination showed that PD-1 signaling blocked lytic granule polarization in NK cells, which was accompanied by failure of integrin-linked kinase, a key molecule in the integrin outside-in signaling pathway, to accumulate in the immunological synapse after NK-target cell conjugation. CONCLUSION: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to the NK cell immunological synapse with concomitant impairment of integrin outside-in signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function.
BACKGROUND: The inhibitory receptor programmed cell death protein 1 (PD-1) is upregulated on a variety of immune cells, including natural killer (NK) cells, during chronic viral infection and tumorigenesis. Blockade of PD-1 or its ligands produces durable clinical responses with tolerable side effects in patients with a broad spectrum of cancers. However, the underlying molecular mechanisms of how PD-1 regulates NK cell function remain poorly characterized. OBJECTIVE: We sought to determine the effect of PD-1 signaling on NK cells. METHODS:PD-1 was overexpressed in CD16-KHYG-1 (a human NK cell line with both antibody-dependent cellular cytotoxicity through CD16 and natural cytotoxicity through NKG2D) cells and stimulated by exposing the cells to NK-sensitive target cells expressing programmed death ligand 1 (PD-L1). RESULTS:PD-1 engagement by PD-L1 specifically blocked NK cell-mediated cytotoxicity without interfering with the conjugation between NK cells and target cells. Further examination showed that PD-1 signaling blocked lytic granule polarization in NK cells, which was accompanied by failure of integrin-linked kinase, a key molecule in the integrin outside-in signaling pathway, to accumulate in the immunological synapse after NK-target cell conjugation. CONCLUSION: Our results suggest that NK cell cytotoxicity is inhibited by PD-1 engagement, which blocks lytic granule polarization to the NK cell immunological synapse with concomitant impairment of integrin outside-in signaling. This study provides novel mechanistic insights into how PD-1 inhibition disrupts NK cell function.
Authors: S K Bromley; W R Burack; K G Johnson; K Somersalo; T N Sims; C Sumen; M M Davis; A S Shaw; P M Allen; M L Dustin Journal: Annu Rev Immunol Date: 2001 Impact factor: 28.527
Authors: Ivana B Alvarez; Virginia Pasquinelli; Javier O Jurado; Eduardo Abbate; Rosa M Musella; Silvia S de la Barrera; Verónica E García Journal: J Infect Dis Date: 2010-08-15 Impact factor: 5.226
Authors: Dongfang Liu; Yenan T Bryceson; Tobias Meckel; Gaia Vasiliver-Shamis; Michael L Dustin; Eric O Long Journal: Immunity Date: 2009-07-17 Impact factor: 31.745
Authors: Yenan T Bryceson; Michael E March; Domingo F Barber; Hans-Gustaf Ljunggren; Eric O Long Journal: J Exp Med Date: 2005-10-03 Impact factor: 14.307
Authors: Panagiota Bouti; Steven D S Webbers; Susanna C Fagerholm; Ronen Alon; Markus Moser; Hanke L Matlung; Taco W Kuijpers Journal: Front Immunol Date: 2021-02-18 Impact factor: 7.561
Authors: Rachel Elizabeth Ann Fincham; Francesca Romana Delvecchio; Michelle R Goulart; Joe Poe Sheng Yeong; Hemant M Kocher Journal: World J Gastroenterol Date: 2021-06-28 Impact factor: 5.742